LLY Q4 2025 Earnings Analysis
Listen On
Available In
Key Highlights
- Revenue and earnings analysis for Q4 2025
- Key financial metrics and performance indicators
- Management guidance and outlook commentary
- Market position and competitive analysis
- AI-generated insights and analysis
Transcript
// Full episode scriptBeta Finch Podcast Script: Eli Lilly Q4 2025 Earnings
Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Eli Lilly's blockbuster Q4 2025 results - and folks, when I say blockbuster, I mean it. This pharmaceutical giant just delivered some truly staggering numbers. But before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Thanks Alex. And wow, where do we even start with these numbers? Lilly just reported 45% full-year revenue growth - that's not a typo, folks - forty-five percent. We're talking about $65.2 billion in revenue for 2025, with earnings per share jumping 86% to $24.21.
It's almost surreal when you see numbers like that from a major pharma company. Jordan, what's driving this incredible performance?
It all comes down to one word: incretins. These are the diabetes and obesity drugs that have become absolute juggernauts. Their key products - we're talking Mounjaro, Zepbound, and their international rollouts - generated over $13 billion in Q4 revenue alone and grew 91% compared to the same quarter last year.
Let's break that down for our listeners. Mounjaro is their diabetes drug, Zepbound is the obesity treatment, but they're essentially the same molecule - tirzepatide - just branded differently for different conditions. And the demand has been absolutely explosive.
Exactly. What's fascinating is how they've captured market leadership. In the US, Mounjaro now has over 55% of new prescriptions in the diabetes incretin market, while Zepbound commands nearly 70% share in the branded obesity market. But here's what really caught my attention - they're not just winning in the US anymore.
Right, their international business has been crushing it. CEO David Ricks mentioned they're now the incretin market share leader outside the US as well. That's a huge development because historically, US pharma companies have struggled to replicate their domestic success internationally, especially in obesity treatments.
And they're not slowing down. Looking ahead to 2026, management guided to revenue between $80-83 billion. That's another 25% growth at the midpoint. But here's where it gets interesting - they're expecting significant pricing headwinds.
This is crucial for investors to understand. Lilly is projecting price declines in the low-to-mid teens for 2026. That's a massive headwind, but they believe volume growth will more than offset it.
The pricing pressure comes from several factors. First, they struck a deal with the US government to provide obesity medicines to Medicare patients for just $50 per month out-of-pocket starting no later than July 1st. That's huge for patient access but means lower prices for Lilly.
They're also facing competition from oral versions of these drugs. During the call, they discussed launching their own oral obesity treatment, orforglipron, which they expect to get FDA approval for in Q2 2026.
The oral competition point is really interesting. When Novo Nordisk launched oral Wegovy recently, instead of cannibalizing existing injectable sales, it actually expanded the overall market. Lilly's management seems confident this trend will continue - that oral options bring new patients into treatment rather than just switching existing ones.
Let's talk about their direct-to-consumer business because this is revolutionary for pharma. They've reached 1 million patients on their US direct-to-patient platform. Think about that - patients are buying prescription obesity drugs directly from the manufacturer, often paying cash.
It's unprecedented, really. CEO David Ricks admitted during Q&A that there's no good historical analog for this many people paying out-of-pocket for prescription medication. He mentioned looking at everything from cosmetics to the old Viagra launch for comparison, but acknowledged this is truly uncharted territory.
Their vial offerings have been particularly successful. These are cheaper versions that patients can inject themselves rather than using pre-filled pens. Zepbound vials now make up one-third of new patient starts across all obesity medications - not just Lilly's, but the entire category.
Beyond the obesity story, there were some other notable developments. Their Alzheimer's drug Kisanlo became the US market leader in amyloid-targeting therapies with over 50% prescription share. And they're making serious investments in AI drug discovery, including a new collaboration with NVIDIA.
The R&D pipeline is massive too. They have 36 active Phase III programs and one of the largest clinical-stage pipelines in company history. CFO Lucas Montarce mentioned R&D expenses will scale up significantly in 2026 to support all these programs.
One thing that struck me from the Q&A was how they're thinking about combination therapies. They released data showing their psoriatic arthritis drug combined with tirzepatide delivered much better results than the arthritis drug alone. It suggests these incretin drugs might have benefits beyond just weight loss.
That's a really important point for the long-term investment thesis. If these drugs prove beneficial for multiple conditions - arthritis, sleep apnea, liver disease - the addressable market becomes even larger.
Looking at the financial metrics, their gross margin held steady at 83.2%, which is impressive given all the pricing pressure they're facing. Their performance margin actually improved to 47.2%, up over 4 percentage points year-over-year.
For 2026, they're guiding to a performance margin between 46-47.5%. They're reinvesting heavily in R&D and marketing to support new launches, but still maintaining excellent profitability.
The capital allocation story is solid too. They returned $2.8 billion to shareholders through dividends and share repurchases in 2025. And they've committed over $55 billion since 2020 to manufacturing expansion - the largest build-out in company history.
So what's the bottom line for investors? Lilly is executing at an incredibly high level in one of the most important drug categories of our generation. The obesity market is still in early innings with mid-single digit penetration, and they're the clear leader.
The risks are real though - pricing pressure, competition, and the uncertainty around sustaining this growth rate long-term. But they seem to be managing the transition well, expanding internationally, and developing next-generation treatments.
They're also proving that direct-to-consumer pharma can work at scale, which could be a competitive moat as other companies struggle to replicate their platform.
Before we wrap up, I want to remind everyone that everything we've discussed today is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Absolutely. Eli Lilly's results show what's possible when a pharmaceutical company hits a genuine breakthrough in a massive market. Whether they can sustain this trajectory will be the key question for 2026 and beyond.
That's all for today's Beta Finch earnings breakdown. We'll be back with more AI-powered market insights soon.
Thanks for listening, and remember - always do your homework before making any investment decisions. Until next time! ---